Phase III IMvigor010: Adjuvant Atezolizumab vs Observation in Patients With High-Risk Muscle-Invasive Urothelial Cancer

May 29-31, 2020; Online at meetings.asco.org/am
Adjuvant atezolizumab did not improve disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma compared with observation.
Format: Microsoft PowerPoint (.ppt)
File Size: 253 KB
Released: June 8, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Exelixis
Pfizer, Inc. and EMD Serono

Related Content

Multidisciplinary commentary on optimal use of HER2-targeted treatment in early and metastatic breast cancer, from Clinical Care Options (CCO)

Aditya Bardia, MD, MPH Sara Hurvitz, MD, FACP Kristi Kay Orbaugh, MSN, NP, AOCNP Danielle Roman, PharmD, BCOP Released: May 10, 2022

Two expert thoracic oncologists discuss novel anti-TIGIT immunotherapies for treatment of NSCLC, from Clinical Care Options (CCO)

person default Ani Balmanoukian, MD person default Jyoti D. Patel, MD Released: May 3, 2022

Diwakar Davar, MD, and Jyoti D. Patel, MD, discuss the role of TIGIT and emerging therapies for targeting TIGIT, including current trial data, from Clinical Care Options (CCO)

person default Diwakar Davar, MD person default Jyoti D. Patel, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 27, 2022 Expired: April 26, 2023

Diwakar Davar, MD, and Jyoti D. Patel, MD, review the role of TIGIT and investigational therapies being evaluated in solid tumors, from Clinical Care Options (CCO)

person default Diwakar Davar, MD person default Jyoti D. Patel, MD Released: April 27, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings